Remove Enterprise Value Remove Entity Value Related Topics
article thumbnail

Mallinckrodt, Endo Merger To Create Pharma Entity Valued At $7 Billion

Benzinga

of the combined entity on a pro forma basis for an implied pro forma enterprise value of$6.7 Endo shareholders will receive $80 millionin cash and own 49.9% of the combined company. After cash consideration,Mallinckrodtshareholders will own 50.1% Full story available on Benzinga.com